Cancers

Blood Suggests Higher Cancer Risk

PLATELETS COUNTS APPEAR TO BE DIRECTLY involved with cancer, suggests a growing body of laboratory research. A new study now shows elevated platelet levels associated with certain cancers.

Today, we take a brief look at how researchers in Ontario (Canada) are opening the door to using a simple blood test to help determine the cancer risk for an individual.

Scanning electron micrograph of blood cells. A human red blood cell, an activated platelet, and a white blood cell (from left to right). https://en.wikipedia.org/wiki/Platelet

Platelets 101

What are platelets? Marlene Williams, M.D., director of the Coronary Care Unit at Johns Hopkins Bayview Medical Center, offers this excellent explanation:

Platelets are the cells that circulate within our blood and bind together when they recognize damaged blood vessels.”

She continues: “When you get a cut, for example, the platelets bind to the site of the damaged vessel, thereby causing a blood clot. There’s an evolutionary reason why they’re there. It’s to stop us from bleeding.”

When I think about the relationship between cancer and platelets, it is usually in the context of anti-cancer treatment. For example, low platelet counts (thrombo-cytopenia — THROM-bo-sigh-toe-PEE-ne-ah) can result from chemotherapy damaging the bone marrow reducing platelet production. Such injury is usually temporary.

Lymphoma and the blood cancer known as leukemia can invade the bone marrow. When the cancer cells occupy significant volumes of the marrow, an individual can have challenges making the platelets that they need.

Types of thrombocytopenia (low platelet count)

The Cleveland Clinic (USA) explains that there are three main classes of thrombocytopenia, including:

  • Platelet destruction (such as an auto-antibody attached to the platelet surface).
  • Platelet sequestration (isolation), for example, in an enlarged liver or spleen.
  • Decreased platelet production associated with certain bone marrow diseases.

Platelets and cancer

Researchers analyzed data from nearly nine million Ontario residents to better understand the relationship between platelet levels and cancer risk. The subjects were enrolled in the provincial health insurance plan and had a routine complete blood count test between 2007 and 2017.

The Canadian researchers matched each patient with cancer to three controls (individuals without a cancer diagnosis) according to age, sex, and healthcare use patterns.

The scientists then calculated the cancer risk associated with each category of platelet counts at intervals up to ten years after a blood test.

Here are the odds ratios for those very high platelet counts. For example, an odds ratio of 4.6 means that those with very high platelet levels had a 4.6-times higher risk of getting ovarian cancer.

Study author Giannakeas observes that “the differences in our findings by cancer type surprised me.” He adds, “Clearly, there is a mechanism on platelets occurring with certain cancer types but not with others, such as breast and prostate cancer.”

Photo by Azure Productions on Unsplash

The increase in relative risk appeared most pronounced for ovarian, lung, kidney, and gastrointestinal cancers (including esophagus, stomach, colorectal, and other gastrointestinal cancers).

Platelets and cancer — My take

Is the elevation in platelets a marker for future cancer, or does it indicate the presence of a current malignancy? The increase in risk appeared most significant in the six months after diagnosing thrombocytosis (too many platelets) and decreased rapidly after that.

These findings suggest that increased platelets may be a marker for the presence of existing cancer, rather than a factor associated with increased cancer risk. Cancer may be causing the platelet increase. If the platelet increase were a marker for future cancer, instead of being associated with current cancer, the risk period would likely be longer than six months.

An elevated platelet count may someday serve (along with other screen tools) as a marker for the presence of some cancer type. Thank you for joining me today. Nothing actionable, but the results hint at a future approach using a simple and relatively inexpensive blood test.

Michael Hunter, MD

I received an undergraduate degree from Harvard, a medical degree from Yale, and trained in radiation oncology at the University of Pennsylvania. I practice radiation oncology in the Seattle area.

Recent Posts

Ukraine: Worn Hearts, Steeled Resolve

I have traveled to Ukraine nearly 20 times. Each visit deepens my respect for how…

6 days ago

Medicaid at a Crossroads: Safe AI, Shifting Policy and the Stakes for People’s Health

Medicaid is one of America’s most complex and essential Federal health programs, serving more than…

3 weeks ago

Global childhood vaccination remains resilient, but equity cracks are widening

In 2024, immunisation data from WHO and UNICEF show that while 115 million infants (89%) received at…

3 weeks ago

Restrictive practices in medicine are holding high-income countries back

A paper in this week’s New England Journal of Medicine (NEJM) is part of a…

3 weeks ago

The Trauma of Witnessing Charlie Kirk’s Murder and PTSD

The psychological effects of public space shootings extend beyond physical harm because they create a…

3 weeks ago

Guns, Race, and Profit: The Pain of America’s Other Epidemic

BOGALUSA, La. — Less than a mile from a century-old mill that sustained generations in…

1 month ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More